摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Selacholeic acid; cis-15-Tetracosenoic acid

中文名称
——
中文别名
——
英文名称
Selacholeic acid; cis-15-Tetracosenoic acid
英文别名
tetracos-15-enoic acid
Selacholeic acid; cis-15-Tetracosenoic acid化学式
CAS
——
化学式
C24H46O2
mdl
——
分子量
366.6
InChiKey
GWHCXVQVJPWHRF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    9.8
  • 重原子数:
    26
  • 可旋转键数:
    21
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY<br/>[FR] CONJUGUÉS BIOACTIFS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
    申请人:UNIV MASSACHUSETTS
    公开号:WO2017030973A1
    公开(公告)日:2017-02-23
    Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    本文提供的自递送寡核苷酸具有高效的RISC进入、最小的免疫反应和非靶效应、无需配方的高效细胞摄取,以及高效和特异的组织分布。
  • [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
    申请人:ARIYA THERAPEUTICS INC
    公开号:WO2019046491A1
    公开(公告)日:2019-03-07
    The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.
    本发明提供了淋巴系统定向脂质前药,其制药组合物,制备这种前药和组合物的方法,以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法,包括向需要的患者施用所提供的脂质前药或其制药组合物。
  • [EN] COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS<br/>[FR] UTILISATIONS ET PROCÉDÉS COSMÉTIQUES POUR DES COMPOSITIONS D'INHIBITEUR D'INDOLINE GRANZYME B
    申请人:VIDA THERAPEUTICS INC
    公开号:WO2014153667A1
    公开(公告)日:2014-10-02
    Cosmetic uses and methods for indoline granzyme B inhibitor compounds in compositions with a cosmetically acceptable carrier. Uses and methods for treating, reducing or inhibiting the appearance of ageing in the skin are provided. Also provided are compositions and formulation for cosmetic uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subjecl. The uses and methods comprise applying/administering an indoline granzyme B inhibitor to a skin, or a portion of a skin of the subject.
    使用和方法用于在与化妆品可接受载体混合的化合物中使用吲哚啶颗粒酶B抑制剂。提供了用于治疗、减少或抑制皮肤衰老的用途和方法。还提供了用于化妆品用途的组合物和配方,以及保持年轻外观、减少衰老外观、抑制衰老外观、减少衰老外观速率、减少皮肤无弹性、减少增加皮肤无弹性速率、保持皮肤弹性和增加皮肤毛囊密度的方法。这些用途和方法包括将吲哚啶颗粒酶B抑制剂涂抹/施用于皮肤或受试者皮肤的部分。
  • [EN] MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS MACROCYCLIQUES DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
    申请人:ACHILLION PHARMACEUTICALS INC
    公开号:WO2018160892A1
    公开(公告)日:2018-09-07
    Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    提供大环补体因子D抑制剂、药物组合物及其用途,以及它们的制造工艺。所提供的化合物包括公式I、公式II、公式III、公式IV、公式V、公式VI、公式VII和公式VIII或其药用可接受的盐、前药、同位素类似物、N-氧化物或孤立的同分异构体,可选地存在于药用可接受的组合物中。此处描述的抑制剂针对因子D并抑制或调节补体级联反应。
  • METHOD FOR THE SYNTHESIS OF DIACIDS OR DIESTERS FROM NATURAL FATTY ACIDS AND/OR ESTERS
    申请人:Dubois Jean-Luc
    公开号:US20100305354A1
    公开(公告)日:2010-12-02
    The invention relates to a process for the synthesis of diacids or diesters of general formula ROOC—(CH 2 ) x —COOR, in which n is an integer between 5 and 14, R is either H or an alkyl radical of 1 to 4 carbon atoms, from natural long-chain monounsaturated fatty acids or esters including at least 10 adjacent carbon atoms per molecule of the general formula CH 3 —(CH 2 ) n —CHR 1 —CH 2 —CH═CH—(CH 2 ) p —COOR, in which R is H or an alkyl radical with 1 to 4 carbon atoms, R 1 is either H or OH, and n and p, which are equal or different and are indices between 2 and 11. The method comprises: during a first step, converting the natural fatty acid or ester by pyrolysis or by ethenolysis, into a ω-monounsaturated fatty acid or ester of the general formula CH 2 ═CH—(CH 2 ) m —COOR, in which m is equal to p or p+1, depending on the nature of the processed fatty acid/ester and the conversion used; during a second step, submitting the product thus obtained to a metathesis or homometathesis reaction for obtaining a compound of the general formula ROOC—(CH 2 ) m —CH═CH—(CH 2 ) m —COOR, or cross-metathesis with a compound of formula R 2 OOC—(CH 2 ) r —CH═CH—R 3 , in which R 2 is either H or an alkyl radical front with 1 to 4 carbon atoms, r is either 0 or 1 or 2 and R 3 is H, CH 3 or COOR 2 , thus defining a cyclic or molecule or not, in order to obtain an unsaturated compound of the general formula ROOC—(CH 2 ) m —CH═CH—(CH 2 ) r —COOR 2 , and during a third step, converting the unsaturated compound into a saturated compound by hydrogenation of the double bond.
    这项发明涉及一种合成一般公式为ROOC—(CH2)x—COOR的二元酸或二元酯的过程,其中n是5到14之间的整数,R是H或1到4个碳原子的烷基自由基,从天然长链单不饱和脂肪酸或酯中合成,这些脂肪酸或酯每分子至少包括10个相邻的碳原子,其一般公式为CH3—(CH2)n—CHR1—CH2—CH═CH—(CH2)p—COOR,其中R是H或1到4个碳原子的烷基自由基,R1是H或OH,n和p相等或不同,是2到11之间的指数。该方法包括:在第一步中,通过热解或乙炔醇解将天然脂肪酸或酯转化为ω-单不饱和脂肪酸或酯,其一般公式为CH2═CH—(CH2)m—COOR,其中m等于p或p+1,具体取决于处理的脂肪酸/酯的性质和所使用的转化;在第二步中,将所得产物进行交叉代谢或同交叉代谢反应,以获得一般公式为ROOC—(CH2)m—CH═CH—(CH2)m—COOR的化合物,或与公式为R2OOC—(CH2)r—CH═CH—R3的化合物进行交叉代谢,其中R2是H或1到4个碳原子的烷基自由基,r是0或1或2,R3是H、CH3或COOR2,从而定义一个循环或不循环的分子,以获得一般公式为ROOC—(CH2)m—CH═CH—(CH2)r—COOR2的不饱和化合物;在第三步中,通过加氢双键将不饱和化合物转化为饱和化合物。
查看更多